Cancer nanomedicines were initially envisioned as magic bullets, travelling through the
circulation to target tumours while sparing healthy tissues the toxicity of classic …

Cancer immunotherapy has emerged as a novel cancer treatment, although recent
immunotherapy trials have produced suboptimal outcomes, with durable responses seen …

Nanoparticles enter tumours through endothelial cells, gaps or other mechanisms, but how
they exit is unclear. The current paradigm states that collapsed tumour lymphatic vessels …

Activation of the innate immune STimulator of INterferon Genes (STING) pathway potentiates
antitumour immunity, but systemic delivery of STING agonists to tumours is challenging. We …

The stimulator of interferon genes (STING) cellular signaling pathway is a promising target
for cancer immunotherapy. Activation of the intracellular STING protein triggers the …

Following its discovery more than 30 years ago, the enhanced permeability and retention
(EPR) effect has become the guiding principle for cancer nanomedicine development. Over …

The delivery of medical agents to a specific diseased tissue or cell is critical for diagnosing
and treating patients. Nanomaterials are promising vehicles to transport agents that include …

Intravenously administered cyclic dinucleotides and other STING agonists are hampered by
low cellular uptake and poor circulatory half-life. Here we report the covalent conjugation of …

Metal complexes are extensively used for cancer therapy. The multiple variables available
for tuning (metal, ligand, and metal–ligand interaction) offer unique opportunities for drug …

Therapeutic targeting of the immune system in cancer is now a clinical reality and marked
successes have been achieved, most notably through the use of checkpoint blockade …